240 related articles for article (PubMed ID: 9428498)
1. Nerve lesions after therapy for childhood acute lymphoblastic leukemia.
Harila-Saari AH; Vainionpää LK; Kovala TT; Tolonen EU; Lanning BM
Cancer; 1998 Jan; 82(1):200-7. PubMed ID: 9428498
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for acute lymphoblastic leukemia may cause subtle changes of the spinal cord detectable by somatosensory evoked potentials.
Vainionpää L; Kovala T; Tolonen U; Lanning M
Med Pediatr Oncol; 1997 Jan; 28(1):41-7. PubMed ID: 8950335
[TBL] [Abstract][Full Text] [Related]
3. Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with motor evoked potentials.
Harila-Saari AH; Huuskonen UE; Tolonen U; Vainionpää LK; Lanning BM
Med Pediatr Oncol; 2001 Mar; 36(3):345-51. PubMed ID: 11241435
[TBL] [Abstract][Full Text] [Related]
4. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
5. Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve.
Vainionpää L; Kovala T; Tolonen U; Lanning M
Pediatr Neurol; 1995 Nov; 13(4):314-8. PubMed ID: 8771166
[TBL] [Abstract][Full Text] [Related]
6. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
7. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
Stark B; Sharon R; Rechavi G; Attias D; Ballin A; Cividalli G; Burstein Y; Sthoeger D; Abramov A; Zaizov R
Cancer; 2000 Jan; 88(1):205-16. PubMed ID: 10618625
[TBL] [Abstract][Full Text] [Related]
8. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia.
Reinders-Messelink HA; Van Weerden TW; Fock JM; Gidding CE; Vingerhoets HM; Schoemaker MM; Göeken LN; Bökkerink JP; Kamps WA
Eur J Paediatr Neurol; 2000; 4(5):225-33. PubMed ID: 11030069
[TBL] [Abstract][Full Text] [Related]
9. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
Freeman AI; Boyett JM; Glicksman AS; Brecher ML; Leventhal BG; Sinks LF; Holland JF
Med Pediatr Oncol; 1997 Feb; 28(2):98-107. PubMed ID: 8986145
[TBL] [Abstract][Full Text] [Related]
10. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
[TBL] [Abstract][Full Text] [Related]
11. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory.
Langer T; Martus P; Ottensmeier H; Hertzberg H; Beck JD; Meier W
Med Pediatr Oncol; 2002 May; 38(5):320-8. PubMed ID: 11979456
[TBL] [Abstract][Full Text] [Related]
12. [Acute lymphoblastic leukemia in childhood. A 10-year experience with the DFCI 81-01 protocol].
de Lacerda AF; Chagas M; Neto A; Vieira E; Ribeiro MJ; Pereira F; Ambrósio A; Sousinha M
Acta Med Port; 1999; 12(7-11):287-92. PubMed ID: 10707467
[TBL] [Abstract][Full Text] [Related]
13. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
[TBL] [Abstract][Full Text] [Related]
14. Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A/B.
Ueberall MA; Skirl G; Strassburg HM; Wenzel D; Hertzberg H; Langer T; Meier W; Berger-Jones K; Huk WJ; Korinthenberg R; Beck JD
Eur J Pediatr; 1997 Sep; 156(9):727-33. PubMed ID: 9296540
[TBL] [Abstract][Full Text] [Related]
15. The role of somatosensory evoked potentials in the diagnosis of AIDS-associated myelopathy.
Tagliati M; Di Rocco A; Danisi F; Simpson DM
Neurology; 2000 Apr; 54(7):1477-82. PubMed ID: 10751261
[TBL] [Abstract][Full Text] [Related]
16. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
[TBL] [Abstract][Full Text] [Related]
17. [Late sequelae of central nervous system prophylaxis in children with acute lymphoblastic leukemia: high doses of intravenous methotrexate versus radiotherapy of the central nervous system--review of literature].
Zając-Spychała O; Wachowiak J
Med Wieku Rozwoj; 2012; 16(2):128-37. PubMed ID: 22971657
[TBL] [Abstract][Full Text] [Related]
18. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
Nishikawa T; Kawakami K; Kumamoto T; Tonooka S; Abe A; Hayasaka K; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2008 Jul; 30(7):519-21. PubMed ID: 18797198
[TBL] [Abstract][Full Text] [Related]
19. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
[TBL] [Abstract][Full Text] [Related]
20. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
